Metraipolis › archive › dc_2b7d9290dc5e

Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma — Europe PMC PMID:41029243

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41029243
DOI
10.1186/s12885-[numero omesso]-1
License (as archived)
solo-consultazione
Archived
2026-11-09T16:50:09.442Z
SHA-256 of the archived text
b4bbcc0f2d831ea253f770fd1c590387006328ea8d97a69abb6095f8bf570ebe
Stable URL of this page
https://metraipolis.com/documento/dc_2b7d9290dc5e

How to cite

Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma — Europe PMC PMID:41029243 — Europe PMC (en), https://europepmc.org/article/MED/41029243 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2b7d9290dc5e (Metraipolis archive dc_2b7d9290dc5e, sha256 b4bbcc0f2d831ea253f770fd1c590387006328ea8d97a69abb6095f8bf570ebe)
BibTeX
@misc{dc2b7d9290dc5e,
  title = {Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma — Europe PMC PMID:41029243},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41029243},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2b7d9290dc5e; sha256 b4bbcc0f2d831ea253f770fd1c590387006328ea8d97a69abb6095f8bf570ebe},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41029243. Agents can read the archived copy with the MCP tool read_document.